🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationPeptide degradation products — looking for input

Peptide degradation products — looking for input

DeniseRN_TPA Thu, Feb 19, 2026 at 4:56 AM 27 replies 997 viewsPage 1 of 6
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Feb 19, 2026 at 4:56 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I actually want to know is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. Happy to be told the question itself is wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
44 14jim_asheville, matt_MKE, Dr.ReproEndo and 41 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Feb 19, 2026 at 5:08 AM#2
DeniseRN_TPA said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

That is correct as far as it goes, and here is where it stops going. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Feb 19, 2026 at 7:08 AM
43 13PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 40 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Feb 19, 2026 at 5:20 AM#3
DeniseRN_TPA said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Pushing back on DeniseRN_TPA here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

Last edited: Feb 19, 2026 at 8:20 AM
42 12PharmHunterJen, TomTeleRx, DoseLogDan and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Feb 19, 2026 at 5:32 AM#4

Taking the question as asked, rather than the general version of it. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Feb 19, 2026 at 11:32 AM
41 11PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 38 others
Reply Quote Save Share Report
mona_PHX
Member
189
890
Dec 2024
Phoenix, AZ
Feb 19, 2026 at 6:33 AM#5
Dr.MetabolicMD said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Same experience, arrived at from the opposite direction. I had assumed I was the exception until I read this.

40 10MariaRD, AussieAnna, BethLabQueen and 37 others
Reply Quote Save Share Report
1236

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register